PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
High-dose chemotherapy with autologous stem cell support is the current standard procedure in
the first-line treatment in younger patients with myeloma fit for intensive treatment.
Current practice in Switzerland for stem cell mobilization is the combination of chemotherapy
and G-CSF stimulation in myeloma patients fit for high-dose chemotherapy with melphalan and
autologous stem cell transplant. In this trial the intravenous application of Plerixafor is
being investigated in respect of the capability of the mobilization of stem cells from the
bone marrow into the peripheral blood. In contrast to the twice daily application of G-CSF
(eg. Neupogen) for several days, Plerixafor has to be injected just one-time.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Treatments:
JM 3100 Lenograstim Plerixafor Vinblastine Vinorelbine